Bortenat 3.5 (Bortezomib) 3.5 mg
Bortenat 3.5 mg contains Bortezomib, a proteasome inhibitor used extensively in oncology. This vial strength (3.5 mg) is the standard dose unit for adult patients.
Manufacturer: Natco Pharma (India). Generic equivalent of Velcade.
Mechanism:
It specifically targets the 26S proteasome within cells. Cancer cells are more dependent on proteasome function for survival than normal cells. By blocking this function, Bortenat induces apoptosis (cell death) in myeloma cells.
✅ Benefit: Effective in patients with high-risk cytogenetics and renal impairment.
Approved for the treatment of:
- Multiple Myeloma: Usually in combination with melphalan and prednisone (for untreated patients) or as monotherapy (for relapsed cases).
- Mantle Cell Lymphoma (MCL): In patients who have received at least one prior therapy.
⚠️ Professional Administration Only. DO NOT GIVE INTRATHECALLY.
Reconstitution for 3.5 mg Vial:
- For Intravenous (IV) use: Add 3.5 ml of 0.9% Sodium Chloride (Final conc. 1 mg/ml).
- For Subcutaneous (SC) use: Add 1.4 ml of 0.9% Sodium Chloride (Final conc. 2.5 mg/ml).
Administration: SC injection is often preferred to reduce the incidence of peripheral neuropathy. Rotate injection sites.
- Hypersensitivity to bortezomib, boron, or mannitol.
- Acute diffuse infiltrative pulmonary and pericardial disease.
- Pregnancy and breastfeeding (Potential hazard to the fetus).
Adverse events may include:
- Neuropathy: Peripheral sensory neuropathy (numbness/pain in hands and feet).
- Hematologic toxicity: Thrombocytopenia (low platelets), neutropenia.
- Gastrointestinal: Nausea, diarrhea, vomiting.
- Infections: Herpes zoster reactivation (antiviral prophylaxis is recommended).
Similar products
What Customers Say
No reviews yet
Your review can be the first!